Eptinezumab + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
74
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Episodic Migraine
Conditions
Episodic Migraine
Trial Timeline
Jun 8, 2023 → Aug 31, 2027
NCT ID
NCT05897320About Eptinezumab + Placebo
Eptinezumab + Placebo is a phase 3 stage product being developed by Lundbeck for Episodic Migraine. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05897320. Target conditions include Episodic Migraine.
Hype Score Breakdown
Clinical
27
Activity
18
Company
7
Novelty
9
Community
10
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05897320 | Phase 3 | Recruiting |
| NCT05452239 | Approved | Completed |
| NCT04965675 | Phase 3 | Recruiting |
| NCT04688775 | Phase 3 | Completed |
| NCT04418765 | Phase 3 | Completed |
| NCT04336449 | Phase 1 | Completed |
| NCT04152083 | Phase 3 | Completed |
Competing Products
19 competing products in Episodic Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Galcanezumab | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| BOTOX + Placebo | AbbVie | Phase 3 | 77 |
| Atogepant 60 mg | AbbVie | Phase 3 | 77 |
| Atogepant + Ubrogepant | AbbVie | Approved | 85 |
| Atogepant + Placebo-Matching Atogepant | AbbVie | Phase 3 | 77 |
| SOM230 + Placebo | Novartis | Phase 2 | 52 |
| AMG334 + Oral Prophylactic | Novartis | Approved | 85 |
| AMG334 (70 mg) Pre-Filled Syringe (PFS) + Placebo Pre-Filled Syringe (PFS) | Novartis | Phase 3 | 77 |
| Erenumab | Novartis | Phase 3 | 77 |
| Placebo + AMG 301 | Amgen | Phase 2 | 51 |
| Placebo + MS Contin (morphine sulfate, controlled release) + EMBEDA (morphine sulfate / naltrexone hydrochloride) | Pfizer | Phase 1 | 32 |
| Eptinezumab + Placebo | Lundbeck | Phase 3 | 74 |
| Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A + Botulinum toxin type A | Ipsen | Phase 3 | 74 |
| IPN10200 + IPN10200 dose A + IPN10200 dose B | Ipsen | Phase 2 | 49 |
| DFN-11 | Dr. Reddy's Laboratories | Phase 3 | 74 |
| Methylprednisolone | Brain Biotech | Approved | 77 |